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Abstract
Background: Improving medication safety is a major concern in primary care settings worldwide. The Salford
Medication safety dASHboard (SMASH) intervention provided general practices in Salford (Greater Manchester, UK)
with feedback on their safe prescribing and monitoring of medications through an online dashboard, and input
from practice-based trained clinical pharmacists. In this study we explored how staff working in general practices
used the SMASH dashboard to improve medication safety, through interactions with the dashboard to identify
potential medication safety hazards and their workflow to resolve identified hazards.
Methods: We used a mixed-methods study design involving quantitative data from dashboard user interaction
logs from 43 general practices during the first year of receiving the SMASH intervention, and qualitative data from
semi-structured interviews with 22 pharmacists and physicians from 18 practices in Salford.
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Results: Practices interacted with the dashboard a median of 12.0 (interquartile range, 5.0–15.2) times per month
during the first quarter of use to identify and resolve potential medication safety hazards, typically starting with the
most prevalent hazards or those they perceived to be most serious. Having observed a potential hazard,
pharmacists and practice staff worked together to resolve that in a sequence of steps (1) verifying the dashboard
information, (2) reviewing the patient’s clinical records, and (3) deciding potential changes to the patient’s
medicines. Over time, dashboard use transitioned towards regular but less frequent (median of 5.5 [3.5–7.9] times
per month) checks to identify and resolve new cases. The frequency of dashboard use was higher in practices with
a larger number of at-risk patients. In 24 (56%) practices only pharmacists used the dashboard; in 12 (28%) use by
other practice staff increased as pharmacist use declined after the initial intervention period; and in 7 (16%) there
was mixed use by both pharmacists and practice staff over time.
Conclusions: An online medication safety dashboard enabled pharmacists to identify patients at risk of potentially
hazardous prescribing. They subsequently worked with GPs to resolve risks on a case-by-case basis, but there were
marked variations in processes between some practices. Workload diminished over time as it shifted towards
resolving new cases of hazardous prescribing.
Keywords: Information technology, Medication safety, Prescribing, Primary care, Clinical pharmacy
Background
The safe prescribing and monitoring of medicines is an
important aspect of health care provision worldwide as re-
cently emphasised by the latest WHO Global Patient
Safety Challenge (2017) “Medication without harm” [1]. In
a retrospective study of prescribing over a period of 12
months in 15 English general practices, the prevalence of
monitoring or prescribing errors in over 6000 unique pre-
scription items was found to be 4.9%, with 18.7% of pa-
tients receiving at least one prescribing or monitoring
error [2]. In studies investigating the prevalence of hazard-
ous prescribing in primary care in the UK using prescrib-
ing safety indicators, it was found that between 5.2 and
5.5% of patients received potentially hazardous prescrip-
tions and 7.6–11.8% of patients had not received recom-
mended monitoring tests, though there was marked
variation between general practices [3, 4].
Information technology (IT) based tools have been uti-
lised in supporting general practitioners and other health
professionals to improve the quality and safety of prescrib-
ing [5, 6]. For medication safety this typically involves
computerised decision support (CDS) at the point of care
[7]. However, CDS tends to suffer from two problems:
firstly, systems often do not fit into clinical workflow since
they interrupt to correct decisions that have already been
taken, and secondly some systems have been seen to gen-
erate too many alerts which causes ‘alert fatigue’ and a
drop in effectiveness after initial positive results [8]. These
problems eventually cause some clinicians to simply ig-
nore all alerts [9, 10]. The pharmacist-led information
technology intervention for medication errors (PINCER)
intervention provided computer-generated feedback about
patients potentially exposed to hazardous prescribing [11].
In contrast to CDS systems, this feedback took place after
the clinical encounter and therefore did not suffer from
those same problems [12]. The PINCER trial demon-
strated that pharmacists working collaboratively with pri-
mary care physicians to act upon the feedback reduced
the numbers of those affected by particular prescribing
safety indicators compared with the provision of feedback
without pharmacist visits [11]. Pharmacists were trained
in educational outreach and root cause analysis techniques
so that they could identify, resolve and prevent potentially
hazardous prescribing and drug monitoring in partnership
with local staff at general practices [13]. The intervention
highlighted the pivotal role of pharmacists in the interven-
tion’s effectiveness. There were, however, indications that
the reductions in risk due to PINCER may be temporary
because the intervention did not necessarily sustain reduc-
tions in incidents of hazardous prescribing for all indica-
tors beyond 6 month follow up [11]. This was in part
because the feedback comprised a single report of data ex-
tracted from local electronic health records, whereas mul-
tiple cycles of feedback would typically be more effective
[14, 15]. The PINCER evaluation identified the import-
ance of integration of the pharmacists into the practice
team particularly in implementing changes however it did
not investigate exactly how the computer-generated feed-
back was used by stakeholders [16].
The Salford Medication safety dASHboard (SMASH)
intervention extends PINCER by providing feedback
through an electronic, interactive medication safety dash-
board alongside support from practice based pharmacists
trained in root cause analysis [17]. The dashboard, that is
refreshed daily, provides feedback about identified patients
exposed to potentially hazardous prescribing and inad-
equate blood-test monitoring. A previous qualitative study
specifically explored the ways in which the full SMASH
intervention was adopted, implemented and embedded in
general practices and revealed that the success of this
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work was critically dependent upon the pivotal role of the
pharmacist and how they and other clinicians and staff
members interacted with each other to create a learning
health system [18]. This previous qualitative study focused
on the ways in which the intervention was integrated into
practice and drew upon Normalisation Process Theory to
understand this process [19].
Interventions based on digital technology such as
SMASH are complex interventions [20–22] that facilitate
quality improvement by providing local teams with tools
to measure and monitor their performance and take ap-
propriate action. It will often depend on the organisational
context, which aspects of clinical performance require im-
provement and how this is best achieved [23]. This com-
plexity resides among other things in the interaction
between various components of the intervention; people
and technology can be reciprocally entwined within a
sociotechnical system [24, 25]. Process evaluations are ne-
cessary to gain insight into why an intervention works or
fails within different contexts and how it can be optimised
[22, 26–31]. The electronic nature of the SMASH dash-
board allows for new opportunities to study the mecha-
nisms through which users interacted with the
intervention quantitatively [32]. It has been recommended
that qualitative and quantitative methods should be uti-
lised together in process evaluations to gain a deeper un-
derstanding of complex pathways and identify the ways
through which intervention components were operationa-
lised and integrated within local settings [28–31].
Dashboards have been utilised in primary care and other
health settings including for prescribing safety [33, 34]. A
recent review concluded that while dashboards might im-
prove clinical outcomes for patients the exact characteris-
tics of dashboards and how they were utilised by clinicians
was not fully understood [35]. In this study, we aimed to
understand the specific ways in which clinical pharmacists
and physicians interacted with the SMASH online dash-
board and how the level of engagement with the dash-
board varied between practices. By doing so this could
enable us to understand how the SMASH intervention
could be operationalised and integrated into practice and
hence understand its impact and sustainability.
Methods
Study design
We adopted an integrated mixed-methods approach [36,
37]. We conducted semi-structured interviews with
study participants, and we harnessed the user log files
produced by the electronic dashboard in order to gain in
depth insights into the ways the dashboard was utilised.
The study was carried out alongside an interrupted
time-series analysis evaluating the impact of the SMASH
intervention in 43 general practices across Salford (a city
in Greater Manchester, UK) which has a population of
over 250,000. We used a mixed-methods study design,
which involved synergistic utilisation of quantitative data
from user interaction logs produced by the dashboard,
and qualitative data from semi-structured interviews.
Whilst the quantitative data was particularly used to as-
sess the objective dashboard usage patterns across all
practices, and the variation between those practices, the
qualitative data was used to explain the patterns ob-
served and explored how practices used the information
extracted from the dashboard to resolve potential medi-
cation safety hazards; which would typically happen out-
side the dashboard.
The SMASH intervention
Full details of the intervention have been published else-
where [17]. Participating general practices within Salford
Clinical Commissioning Group (CCG) received access to
an electronic medication safety dashboard and support
from clinical pharmacists working within the practices.
The initial intervention period was 3 months but partici-
pants were free to continue using the dashboard after
this time period. The dashboard utilised a set of pre-
scribing safety indicators (Additional file 1) (e.g. the
number of patients with a history of peptic ulcer or
gastro-intestinal bleeding prescribed a non-steroidal
anti-inflammatory drug (NSAID) without a gastro-
protective medicine) and presents the resulting informa-
tion to its users in both aggregated form and as lists of
individual patients with potential safety hazards [11].
Five types of pages were available within the dashboard:
 Practice summary: practice size, number and
percentage of patients currently affected by at least
one indicator, and number of patients affected by
multiple indicators. This is typically the landing page
when accessing practice-specific data.
 Table overview: a table listing for each indicator the
number and percentage of patients who are
currently at risk, comparisons with the CCG
average, and the trend over time. By default, the list
of indicators was presented in descending order of
the number of at-risk patients.
 Chart overview: same as the overview table but
represented using bar and line charts.
 Patient lists: a list of NHS numbers of patients who
are identified by the dashboard to be currently at
risk for the selected indicator, including information
about other indicators for which they are at risk and
since when.
 Indicator information: explanation and evidence of
the selected safety indicator and suggestions for
taking corrective action; supported by references to
scientific literature. In contrast to the other types of
pages this was static information.
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Clinical pharmacists were trained to work collabora-
tively with practice staff to resolve episodes of potentially
hazardous prescribing and drug monitoring, and utilised
root cause analysis techniques to identify and implement
organisational ‘systems’ changes to prevent their future
occurrence. Whereas some pharmacists were employed
directly by a single practice and had already been in their
role at the commencement of the intervention, others
were employed by the local hospital trust and were
aligned to groups of general practices in different
neighbourhoods.
Participants
Forty-three general practices participated in the SMASH
intervention across the Salford Clinical Commissioning
Group (CCG). All 44 general practices in Salford were
eligible to participate in the study if they contributed to
the Salford Integrated Record (SIR; a data warehouse
containing primary care data from contributing practices
across Salford). One practice wanted to participate in
the SMASH intervention but was unable to do so as it
did not contribute to SIR. Practices consented to take
part in the study and began to receive the SMASH inter-
vention thereafter [17]. Participants for the interviews
were purposefully sampled from practices to reflect the
different contexts in which SMASH was implemented,
including variations in practice size, locality measures of
social deprivation and type of electronic patient record
software used (EMIS Web or VISION v3). General Prac-
titioners (GPs), practice nurses, practice administrators
and managers, and pharmacists working within each
practice included were eligible for inclusion in the inter-
views. Individual participants were recruited on a pur-
posive basis through direct contact with the pharmacist
delivering the SMASH intervention at the practice(s) in
question. Additional written informed consent was taken
from individual participants prior to each interview,
which included consent for the interviews to be audio
recorded and transcribed verbatim and for anonymised
quotations to be used in reports.
Data collection and analysis
We extracted the quantitative data from user interaction
logs produced by the dashboard during the first year of
the intervention in each practice. The logs included page
views, mouse clicks, hovers, and key strokes. Therefrom
we determined the number and duration of interactions
within practices, which pages (e.g. which indicators,
which feedback modalities) were viewed, and under what
circumstances that occurred. We compared the quanti-
tative user interaction metrics between practices and
user groups (e.g. pharmacists and practice staff) and over
time using medians and interquartile ranges (IQRs) for
non-normal distributions. We assessed the relationship
between dashboard use and the number of patients po-
tentially exposed to one or more medication safety haz-
ards using Pearson’s correlation coefficient. Data analysis
was undertaken using R statistical software version 3.3.0
(R Foundation for Statistical Computing).
The semi-structured interviews were carried out face-
to-face by a qualitative health researcher (MJ) between
April and December 2016. The researcher was not known
to participants at the time of the interviews. Interviews
were primarily conducted at the general practice where
the participant was working. Five interviews were con-
ducted at The University of Manchester and one at the
Salford (CCG) offices. We analysed the qualitative inter-
view data using a thematic template analysis approach
[38]. A set of thematic codes was developed from inde-
pendent reading of the first six interviews by three of the
authors (MJ, RNK, DLP). This set of codes was applied to
the all the transcripts using the NVivo version 10 qualita-
tive data management software. In an iterative approach,
the template was then further developed and adapted as
the transcripts were coded. Finally, the coded extracts
were analysed, and emerging themes highlighted which
formed the basis of the results detailed below.
Quantitative and qualitative data were collected concur-
rently, analysed separately and then integrated in a process
of using the quantitative and qualitative data to validate,
explain, and complement their separate findings. This in-
volved a strategy of synthesizing and weaving of the data
based on the approach described by Fetters et al. (37),
whereby the qualitative data was further explored to find
explanations in the quantitative and vice versa.
Results
The 43 Salford general practices started receiving the
SMASH intervention between 18 April 2016 and Sep-
tember 2017. During the study period the dashboard
logged 2626 sessions by 55 users (25 pharmacists and 30
practice staff). Twenty-five interviews were undertaken
with 22 participants (12 pharmacists, four GPs, one
practice nurse, one practice administrator, one practice
manager and three CCG managers) working in 18 (42%)
different general practices and at the CCG. One interview
was conducted jointly (practice manager and practice ad-
ministrator). Interviews lasted between 14 and 62min,
with three pharmacists and one GP interviewed longitu-
dinally on two occasions in order to capture how the
intervention might be sustained (see Additional file 1).
Interactions with the dashboard
Primary users of the dashboard and frequency of use
Table 1 presents the frequency and duration of interac-
tions with the dashboard in the participating practices
throughout the first year of receiving the SMASH inter-
vention. Practices interacted with the electronic dashboard
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with a median average frequency of 6.6 (IQR, 4.2–9.3)
times per month. The dashboard was primarily used by
pharmacists who interacted a median of 5.9 (IQR, 3.3–8.2)
times per month as opposed to local practice staff who
interacted 0.5 (IQR, 0–1.5) times per month.
Both practice staff and pharmacists considered the
dashboard as something for the pharmacist to use.
Whilst pharmacists sought to encourage GPs to use the
dashboard, the GPs themselves made decisions on
whether they needed a user account based on whether
they thought they would access the dashboard:
“I have not seen anyone look at the dashboard, apart
from the, I think the practice manager may have ac-
cess to it, I’m not sure. But I’ve not seen them. The
only way they find out about the dashboard is;
through me” (Pharmacist –P7)
“…we’ve only got one lead GP [and] four associate GPs
so they don’t…it depends on what they want to get in-
volved with. So, they’re not salaried so they can’t just be
given all of the work for the GP practice. It’s very much
at their discretion what projects they want to get in-
volved with and if they don’t want to get involved, they
don’t want to get involved.” (Pharmacist -P1)
Similarly, variation in use of the dashboard was also de-
scribed by one GP who explained that whilst some GPs at
their practice perceived they would not use the dashboard,
others had access to view evidence summaries or made
decisions to take the lead on the use of the dashboard.
“So, at the meeting we said who wants access to this?
We’ve said the people that want access I've given
them the email link so that they can login. Some
people (GPs) have just said, they don't want access,
[…] there is no point because I'm not going to look at
it. Then a couple of people have said I want to be
able to get these. I want to be able to get the evi-
dence for the educational point of view.” (GP1)
Figure 1 presents examples of typical user patterns found
in individual practices concerning the frequency of dash-
board interactions by pharmacists and practice staff over
time. Although all practices had created user accounts for
practice staff to access the dashboard, in 24 (56%) prac-
tices non-pharmacy staff never or hardly interacted with it
(e.g. Fig. 1a and b). Pharmacists experienced barriers to
using the dashboard as a result of competing priorities in
the practice relating to tasks not directly associated with
the intervention, such as repeat prescription requests or
medicine reconciliations of patients discharged from the
hospital. One such practice pharmacist described her role
as involving a range of such activities;
“I end up having my fingers in a few different pies. I
look after clinical post and letters, transfer of care out
of hospital, so I do medicines reconciliation kind of
back out to the GP side of things. I do telephone calls,
so I’ve got my own telephone clinic where patients with
medication queries, problems, supply issues rather
than going through to the GP they now come through
to myself to sort out. [...] So I do a lot of medicines in-
formation queries for the doctors about doses avail-
ability of treatment, NICE guidance and the same for
patients if they ring up as well.” (Pharmacist -P1)
As a consequence, they “would need to take some of my
time out of the day to particularly look at the SMASH
dashboard.” (Pharmacist -P1)
The frequency with which practice staff, including phar-
macists, interacted with the dashboard declined over time
(Fig. 1). While during the first 3 months the median aver-
age frequency of dashboard interactions was 12 (IQR, 5–
15.2) times per month; during the rest of the study period
this was 5.5 (IQR, 3.5–7.9) times per month (Table 1).
This pattern was consistent with the way pharmacists de-
scribed using the dashboard in that they would initially in-
vestigate all the patients already highlighted as being
potentially at risk from hazardous prescribing, and then
once having reviewed those patients use the dashboard to
investigate new emerging cases:
“I think to start with it was very much an active tool to
be used. I think its use will change, because I have cer-
tainly seen its use change from when we first got, like I
say, when it was looking at the...we didn’t have massive
numbers but, you know, the practice was looking at the
fifty patients that were already affected by the indica-
tor. Whereas, what we are doing now, looking at the
new patients that are just coming on, it’s a different
way of using the same tool.” (Pharmacist -P2)
Similarly, other pharmacists reported checking the dash-
board on “probably, every week, two weeks, four weeks,”
(Pharmacist-P12) or to “see if any new cases have come up
and I check that on a monthly basis.” (Pharmacist -P7).
Once the number of at-risk patients from one indicator
was reduced, the pharmacist identified new cases as a way
active surveillance of the prescribing in practice.
“Well what I would like is for the pharmacist to keep
using the dashboard to identify new cases, and then
probably periodically for me or for the pharmacist to
look at the graphs and just check that the graphs are
not crawling back up again.” (GP1)
Whereas in nearly all practices the overall dashboard in-
teractions declined as pharmacists started using the
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Table 1 Frequency and duration of dashboard interactions in the 43 participating general practices in Salford during the first year of
the SMASH intervention. All presented data are medians (interquartile range) across practices
Median average number
of views per month (IQR)
Median average time
spent in minutes per
month (IQR)
Median total number
of at-risk patients (IQR)
Users
Any user 6.6 (4.2–9.3) 113.8 (74.1–183.2)
Pharmacists 5.9 (3.3–8.2) 104.7 (51.2–136.0)
Practice staff 0.5 (0.0–1.5) 5.3 (0.0–27.6)
Time
First quarter 12.0 (5.0–15.2) 217.4 (108.4–319.6)
Second quarter 4.5 (2.8–7.4) 69.6 (37.7–102.8)
Third quarter 6.3 (3.7–10.2) 90.4 (50.0–172.2)
Fourth quarter 5.7 (2.7–9.3) 88.4 (27.4–155.9)
Dashboard pages
Practice summary 9.1 (5.3–14.2) 181.5 (66.9–289.0)
Table overview 18.4 (12.2–28.9) 765.9 (380.6–1132.9)
Chart overview 0.9 (0.4–3.0) 25.2 (4.6–119.2)
Indicator information 0.5 (0.2–1.0) 67.0 (4.5–228.8)
Patient list (any medication safety indicator) 19.3 (14.1–35.6) 2907 (1722.0–5371.3) 67 (45–128.5)
Patient lists for specific types of medication safety risks
1. Prescription of an oral NSAID without co-prescription
of an ulcer-healing drug in a patient aged ≥65 years
4.4 (2.5–9.0) 747.9 (338.9–1307.8) 26 (11.5–42.5)
2. Prescription of an oral NSAID without co-prescription
of an ulcer-healing drug to a patient with a history of
peptic ulceration
0.3 (0.1–1.0) 13.1 (0.4–92.2) 1 (1–3)
3. Prescription of an antiplatelet drug without co-prescription
of an ulcer-healing drug to a patient with a history of peptic
ulceration
2.0 (0.5–2.8) 224.4 (98.1–456.4) 4 (2–6.5)
4. Prescription of warfarin or NOAC in combination with
an oral NSAID
1.3 (0.5–1.9) 98.7 (39.3–211.7) 4 (2–6)
5. Prescription of warfarin or NOAC in combination with
an antiplatelet drug without co-prescription of an
ulcer-healing drug
1.3 (0.8–2.5) 130.3 (77.5–358.2) 4 (2–9)
6. Prescription of an aspirin in combination with another
antiplatelet drug without co-prescription of an ulcer-healing
drug
2.5 (1.1–3.8) 345.5 (142.6–532.6) 8 (5–13)
7. Prescription of a non-selective beta-blocker to a patient
with asthma
3.8 (2.0–5.5) 600.3 (358.0–914.2) 15 (8–28.5)
8. Prescription of a long-acting beta-2 inhaler (excluding
combination products with inhaled corticosteroid) to a
patient with asthma who is not also prescribed an inhaled
corticosteroid
0.8 (0.0–1.7) 65.2 (0.0–188.6) 2 (0–6)
9. Prescription of an oral NSAID to a patient with heart failure 0.8 (0.3–1.8) 50.9 (5.5–123.0) 2 (1–5)
10. Prescription of an oral NSAID to a patient with chronic
renal failure (eGFR< 45)
0.5 (0.2–1.3) 55.7 (0.8–114.8) 3 (1.5–5)
11. Prescription of methotrexate without both a recent full
blood count and a recent liver function test
1.2 (0.7–2.3) 158.2 (70.3–315.1) 4 (2.5–6)
12. Prescription of amiodarone without a thyroid function test 1.5 (0.8–3.3) 191.7 (40.3–358.3) 4 (2–6)
Multiple medication safety indicators 0.3 (0.1–0.7) 17.5 (0.8–158.0) 4 (2–7)
NSAID nonsteroidal anti-inflammatory drug. NOAC novel anticoagulants such as apixaban, dabigatran or rivaroxaban. eGFR estimated Glomerular Filtration Rate.
Antiplatelet drugs are aspirin, clopidogrel, prasugrel and ticagrelor. Peptic ulceration includes upper gastrointestinal bleeds, but does not include peptic ulcer
surgery, gastritis, duodenitis or oesophageal varices. Ulcer-healing drugs include the PPIs and H2-antagonist – it does not include misoprostol, sucralfate
or bismuth
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dashboard less frequently, in 12 (28%) practices the
interactions by the local staff excluding pharmacists
increased (e.g. Fig, 1c and d). In 7 (16%) practices
there was mixed use of the dashboard by both phar-
macists and practice staff. This was reflected in the
qualitative interviews in the perceptions of this prac-
tice pharmacist.
“I think I can but I think it’s always going to remain
with the pharmacist here. I don’t think there’s go-
ing to be a GP who suddenly becomes very inter-
ested in it and who decides to take SMASH off
my hands and lead on SMASH here. It might
happen at a bigger practice where you’ve got
maybe a few more partners. You might be able to
get a pharmacist and GP working alongside each
other, so maybe together, once a month, they ac-
cess a SMASH dashboard and sit together.”
(Pharmacist -P1)
The frequency with which practices used the dashboard
was correlated with the number of patients identified by
the dashboard to be potentially exposed to one or more
prescribing safety indicator hazards (Fig. 2; Pearson’s r =
0.63, p < 0.001).
Feedback modalities accessed, and areas of medication
safety focused on by dashboard users
Users spent a median of 113.8 (IQR, 74.1–183.2) minutes
per month interacting with the dashboard (Table 1); and
had similar between-practice variation as the frequency of
dashboard use. Dashboard sessions had a median dur-
ation of 14.3 (IQR, 3.9–29.7) minutes. During their
interactions users predominantly viewed the practice
summaries (9.1 [IQR, 5.3–14.2] times per month),
table overview of all prescribing safety indicators (18.4
[IQR, 12.2–28.9] times per month), and lists of identi-
fied patients exposed to one or more indicators (19.3
[IQR, 14.1–35.6] times per month). Users scarcely
accessed chart overviews and background evidence
about the prescribing safety indicators.
Pharmacists typically started from the practice sum-
maries and table overviews to gain an overview of the
most urgent or common types of medication safety
hazards and patients who were exposed to multiple
indicator types identified by the dashboard, but also
the ones that were ‘quick wins’ - hazards that were
perceived as easier to resolve. This typically involved
going back and forth between the table overview and
various patient lists (i.e. for different medication
safety indicators).
Fig. 1 SMASH dashboard logins by pharmacists and local practice staff per month. Number of SMASH dashboard logins by pharmacists and local
practice staff per month, over the first 12 months of the intervention, in four different general practices. The four practices were chosen to
illustrate the variety of patterns found across all 43 participating general practices
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“Yeah, so when I first started, they wanted me to
focus on the people who were affected by mul-
tiple indicators first, because they deem those to
be the most risky […] So then once we’d cracked
those, then we went on…I did some of the easier
ones, so the monitoring ones that are quite sim-
ple to sort out and then I’m in the middle of
attacking the biggest one, so the 76 people are
affected by the over 65s on NSAIDs…” (Pharma-
cist -P3)
This corresponded with the finding that users spent
most of their time viewing the patient lists of those
prescribing safety indicators that had the highest
number of at-risk patients (Table 1). This particularly
concerned the indicators: ‘Prescription of an oral
NSAID without co-prescription of an ulcer-healing
drug in a patient aged ≥65 years’ (747.9 [IQR, 338.9–
1307.8] minutes per month); ‘Prescription of a non-
selective beta-blocker to a patient with asthma.’
(600.3 [IQR, 358–914.2] minutes per month); and
‘Prescription of aspirin in combination with another
antiplatelet drug without co-prescription of an ulcer-
healing drug’ (345.5 [IQR, 142.6–532.6] minutes per
month). Over time the patient lists were viewed with
lower frequency and duration as users focused upon
looking for new cases.
Workflow to resolve medication safety hazards identified
by the dashboard
Once pharmacists and/or practice staff had identified pa-
tients from the various lists presented in the dashboard, a
series of different activities related to medicines safety
were initiated to address instances of high-risk prescrib-
ing. These different activities were characterised in three
ways: by verifying information, in reviewing patients and
decision making.
Verifying the information in the dashboard
Verification involved checking that the information in the
dashboard was correct and checking the relevance or ap-
propriateness of the alert. One pharmacist reported that
they would “check that actually what the dashboard is tell-
ing me is current” (Pharmacist -P10) with regard to the pa-
tient’s repeat medications by cross referencing the
dashboard with the patients’ health records. Similarly, an-
other pharmacist spoke of making “sure that each indica-
tion is valid” (Pharmacist -P2). Pharmacists verified the
information in the dashboard against the appropriateness
of the alert to the specific needs of patients and to “make
sure it was relevant” (Pharmacist P12). This could involve
decisions as to the appropriateness of changes to medica-
tions that patients had been on for many years and was
seen as “a bit awkward, trying to have that conversation
for something that’s been longstanding for such a period of
Fig. 2 SMASH dashboard logins compared to the number of patients potentially exposed to medication safety hazards. Average number of
SMASH dashboard logins across the 43 participating practices compared to the number of patients potentially exposed to one or more
medication safety hazards during the first 12 months of the intervention
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time” (Pharmacist -P3). Pharmacists reflected upon the
difficulties of assessing the appropriateness of prescribing
or de-prescribing medicines. One pharmacist discussed
how the practice they were working in had concerns about
taking patients off medicines:
“…they (the doctors) were a little bit concerned about
us like taking everyone off NSAIDs without thinking
about what alternative they were going to have for
pain relief; because they are really effective drugs for
like certain types of pain, so they were concerned that
I was going to say, take all these people off NSAIDs
and leave them in pain.” (Pharmacist -P5)
Alternatively, another pharmacist reflected upon the appro-
priateness of adding to the patient’s medication burden.
“…a patient on a PPI (Proton-pump inhibitor) they
are on an NSAID, it just puts you in a direction of
making an intervention that maybe isn’t necessary.
So, it’s something that I have brought up, something
that we need to look at from a training perspective
for more junior pharmacists, that they are not just
going in and starting PPI’s on patients without actu-
ally checking that the patient needs the NSAID. Be-
cause, potentially, what you were doing there is just
adding to the polypharmacy.” (Pharmacist -P10)
It was perceived that with such decisions to be made,
it was important that “it (the use of the dashboard)
needs to be clinically minded, well, clinical pharmacists
who are using it” (pharmacist -P10)
Reviewing patient clinical records
Reviews involved working through those patients listed by
the dashboard as being potentially at risk from hazardous
prescribing and reviewing the patient’s electronic health
records. Pharmacists described working through a list of
those affected by a particular prescribing safety indicator
in order to reduce the number of affected patients:
"So […] I spend my time working my way throsgh
each indicator, from that I look at each patient, find
out the ins and outs of it, work out an action plan
and then I will send that to the relevant person or
take the appropriate action. So I might do things like
ringing a patient up, getting doctors to write pre-
scriptions, sending a letter for somebody to come in,
documenting everything that I’ve found in the notes
and then keep moving on to the next indicator"
(Pharmacist-P3)
This iterative process of going through the patient lists
and reviewing the local records may explain that in
practices throughout the study period users spent a me-
dian average of 2907 (IQR, 1722–5317) minutes, or 48.5
h, per month having opened a dashboard page contain-
ing patient lists.
The information in the dashboard became a starting
point for conducting “an initial look at the patient’s
notes (to) then decide if there are issues on there, we need
to contact the patient” (Pharmacist 6). Review strategies
required exploring the patient’s clinical record as de-
scribed by this pharmacist;
“So I’ve pulled off the data, put it onto a spreadsheet,
gone through individually, gone through each indi-
vidual NHS number[…], pull up the patient straight
away and I’ve then gone into medicines, looked up
why they are flagging, if I can’t see a reason why,
then gone into the consultations and gone back
through the history.” (CCG Pharmacist 3)
The process of review, resulting from information in the
dashboard, was further developed by pharmacists to
undertake a wider and more holistic review of patients.
Pharmacists described these actions as “like some
thought process of the history of the patient and what’s
actually going on and why are they on these drugs.”
(Pharmacist -P5). These more comprehensive reviews
were seen as utilising the dashboard as a starting point
that would allow further potential medicine issues to be
explored.
“So, we are using it as a way to guide us, in terms of
what medication patients will focus on, but when we
look at those patients, we’re obviously looking at the
indicator that flags, but also making sure we look at
the wider patient as well, because we don’t want to
go in and just fix something, like order a blood test,
and realise there’s other issues,[...] that also need re-
solving. So, we’re using it as a way of catching the
patients, but then looking at the whole patient not
just one particular indicator.” (Pharmacist -P6)
Decision making
The use of the dashboard involved processes of commu-
nication and collaboration. Having explored the infor-
mation contained in the dashboard, the pharmacists
might pass this to GPs to make additional clinical deci-
sions. This might involve brief verbal communication,
email or electronically through the practice clinical pa-
tient record system (i.e. instant messaging). GPs were
passed information to recommend changes to patients’
medicines or to review patients. One pharmacist felt it
important to follow up a patient by having a discussion
with the doctor.
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“And I went back to that practice this morning to
speak to the GP about them because I didn’t want to
just leave – it was nearly two sides of A4 of maybe
we could do this – and not follow that up personally.
[...] But I need to speak to the GP first because it’s
quite an in-depth patient.” (Pharmacist - P9)
The pharmacist and clinician might also work together
to decide upon the “best course of action” (Pharmacist
-P5). Such action planning required meeting with clini-
cians and built upon the findings within the dashboard
“A few of the practices, I am covering four practices
currently, so in two of those I am meeting with the
GPs weekly to go through the findings from the dash-
board, what I think the action should be and then
we have agreed an action plan and then come up
with a plan really.” (Pharmacist -P10)
The engagement with GPs was interlinked with ways of
accessing and interacting with the dashboard as this
pharmacist reflected
“Because by the time I had reviewed them I would
have then had to make a decision, do I take those
few patients to the GP now, or do I review all fifty
patients and it take me two or three weeks to do it
and then take them all. And the risk is that you for-
get the exact details of the original patients when the
GP starts then saying, oh, as he got this condition, or
what was his bloods doing or when...” (Pharmacist
-P2)
Discussion
This study explored the interaction and engagement of
healthcare staff with a medication safety dashboard in
general practice. By understanding the frequency and
duration of interactions, the variation of interactions be-
tween users and the workflows in the dashboard interac-
tions we could explore how such tools may be utilised
and the ways in which they might facilitate the long
term sustainability of interventions to improve medica-
tion safety. We found that interaction with the SMASH
dashboard varied markedly between general practices,
with respect to the frequency of use, engagement by the
range of practice staff and the extent to which engage-
ment by pharmacists continued, or tailed off, over time.
Practices with a higher number of at-risk patients used
the dashboard more frequently. In half of the practices
pharmacists were the sole users of the dashboard,
whereas in the other half local practice staff also played
a moderate to active role. Overall, the dashboard use
transitioned over time from intensive use involving re-
view of existing potential prescribing or monitoring
hazards (starting with the most urgent and common
ones), towards regular but less frequent checks of the
dashboard to see if “new cases” required further investi-
gation. The dashboard was utilised to improve medica-
tion safety by initiating three steps; once potentially at-
risk patients were identified from the dashboard, phar-
macists would typically respond by firstly verifying the
risk by examining the patients’ electronic health records.
They would then review the records in order to decide
whether a change to the patient’s medication regiment
was required before undertaking a decision-making
process (often in collaboration with general practi-
tioners) to resolve the risk.
Adaptation of workflow and work practices in re-
sponse to information technology interventions in pri-
mary care has been highlighted elsewhere in the
literature [8, 39–41]. How the SMASH dashboard was
integrated into routine practice was an important finding
of our study and was related to the variation in users
and the differences in engagement by users. Pharmacists
clearly engaged with the dashboard more than did GPs
and other practice staff. This was related to the ways in
which practices were able to adapt and evolve the inter-
vention so it fitted well into their clinical workflow. The
adaptation here typically entailed, particularly at the start
of the intervention, the pharmacists working alone
through lists of patients identified by the dashboard.
Pharmacists in turn involved GP staff to make decisions
with regard to the resolution of the hazard. As the high
number of hazards and associated workload decreased,
GP staff in some practices started using the dashboard
primarily to check new cases. Pharmacists and GPs
worked together to use the information in the dashboard
to check records and make decisions on patients’ medi-
cations. Previous research has suggested that interven-
tions utilising information technology can facilitate new
working practices and collaborations between health
professionals [42, 43]. Interactions and relationships af-
fected the use of the dashboard particularly where com-
munication in the form of feedback from the pharmacist
accessing the system to the GPs ensured that medication
safety actions were taken. This finding aligns with what
Klecun has described as a “sociotechnical network” in
which “implementation is an ongoing social process influ-
enced by stakeholders’ needs, interests, norms and ways
of doing things” [43]. Both this network and the dash-
board allowed the pharmacists to utilise it for medica-
tion safety activities. A similar intervention to improve
prescribing safety in primary care, which provided elec-
tronic feedback but did not involve pharmacists, found
variations in implementation and differences in practice
engagement, and that collective engagement within prac-
tices, particularly from clinicians, led to more successful
implementation [44]. This variation might also be
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explained in that unlike the previous PINCER trial [11,
16] pharmacists in the SMASH intervention stayed with
the practices beyond a three-month intervention period.
As such this may be more reflective of how this inter-
vention may be used and sustained in everyday practice
in the longer term.
Strengths and potential limitations
A particular strength and novelty of our study is the tri-
angulation of qualitative and quantitative data. The
quantitative data examined patterns of use of the dash-
board across all participating practices, whereas the
more in-depth qualitative data from a sub-sample off
those practices helped to explain some of the findings
observed from the quantitative data allowing for conver-
gence of information from different sources. For example,
the declining trend in the frequency with which the dash-
board was used could be explained by pharmacists dis-
cussing the influence of competing priorities and how,
after resolving more cases at the start of the intervention,
they then would only check for new cases of hazardous
prescribing. By adopting such a mixed-methods approach
including interviews with a range of users at different time
points in the intervention, we were able to understand
how the intervention was used in practice.
A limitation is that fewer practice staff were inter-
viewed than pharmacists. There were difficulties in
recruiting GPs generally because of time pressures and
workload, and because fewer numbers accessed the
dashboard at all or as regularly as pharmacists. A limita-
tion of analysing user log files is that we were unable to
verify whether users logged into the dashboard with
their own user accounts or whether multiple users (e.g.
pharmacists together with a GP) were using the dash-
board together on the same computer. Furthermore, in
busy clinical practice users may have been distracted
while logged into the dashboard to attend to other clin-
ical work. This may have led to overestimating the
amount of time users spent in the dashboard. However,
we expect that the overestimation has been limited be-
cause users were automatically logged out 12 min after
the last mouse click, and the session duration was calcu-
lated based on the last user action (e.g. a mouse hover)
in the dashboard.
Implications for further research, policy and practice
The important implications for this study are the ways
in which use of medication safety dashboards such as
SMASH can be integrated into practice. This integration
and sustainability was evident in that the workload di-
minished over time, that users focused upon key areas in
the dashboard at the start of the intervention period and
in the ways the dashboard use integrated with workflows
and work practices.
Using feedback to improve primary care medication
safety can have many advantages over alerts by CDS sys-
tems, but requires pharmacist support which is
resource-intensive, and may not have lasting effects
across all outcomes, as demonstrated by the PINCER
trial [11, 16]. The SMASH dashboard improves on PIN-
CER by providing continuous rather than one-time feed-
back. The SMASH intervention required a high level of
pharmacist input at the start of the intervention period
followed by ongoing availability. Recent policy interven-
tions to increase the availability of pharmacists working
in general practices across England has helped to en-
hance the PINCER approach used in the SMASH inter-
vention. The daily updates on patients exposed to
potentially hazardous prescribing in the SMASH dash-
board has helped to support medicines optimisation in
line with the increased availability of pharmacists working
in general practices. In addition, GP staff were also given
access to the dashboard to enable them to engage with the
intervention particularly as pharmacist involvement di-
minished following the more intensive initial intervention
period; anticipating that the workload associated with im-
proving medication safety would be much less by that
time. Our study findings indicate that this workload re-
duced considerably over time, and once the initial high
numbers of at-risk patient cases were resolved, users
moved to less frequent surveillance for new cases. In some
practices GP staff became involved in using the dashboard
after pharmacist activity reduced. There was however con-
siderable variation in practice staff involvement between
practices; and in many, pharmacists still performed infre-
quent but regular checks of new cases of potentially haz-
ardous prescribing identified by the dashboard. This
implies that it would be feasible to make SMASH, and
similar interventions in the future, sustainable in that they
can continue to have effect after a resource-intensive
period of pharmacist outreach since the dashboard rou-
tinely provides daily checks and the flexibility to work on
key areas with the greatest need or highest risk.
The real-time information in the dashboard allowed users
to recognise the new cases that required such resolution.
That these were easily identifiable in the dashboard and
that they were easily verified by users facilitated their reso-
lution therefore helped to reduce user interactions to man-
ageable and sustainable levels with a focus upon new cases.
Future development of similar interventions should con-
sider the key areas in the early stages of adoption, before
moving towards surveillance and normalisation as part of a
wider strategy to achieve long term sustainability and im-
pact [45]. Additionally, this might facilitate further develop-
ment of the SMASH dashboard with new indicators being
successfully introduced over time if these new indicators
were acted upon in a similar way and with similar levels of
engagement to manage any additional workload.
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A key finding of our study illuminates the ways that
workflow and work practices were implicated in the
integration of the intervention into practice. Since the
intervention was pharmacist-led the main users of the
dashboard were practice-based pharmacists, but their
value was important to the intervention. Pharmacist
activity with the dashboard involved responding to
the safety signals and verifying the information pro-
vided by the SMASH dashboard by reviewing patients’
health records. Beyond these early phases, the
decision-making process to resolve cases often in-
volved a collaborative approach with the pharmacist
communicating with GPs. In the future similar inter-
ventions might utilise pharmacist involvement whilst
also providing the support and engagement from
practices, particularly in the long term. In light of this
it would be of interest to explore how similar inter-
ventions might operate as the clinical role of pharma-
cists evolves, for example in the UK with growing
numbers of pharmacists becoming independent pre-
scribers. In this study, pharmacists highlighted bar-
riers to dashboard use that could involve competing
work priorities. As the role of clinical pharmacists in
general practice evolves, it will be important to ex-
plore how their work is integrated with such medica-
tion safety dashboards. With the national roll out of
prescribing safety indicators as a quality measure the
findings here may inform the optimal use in primary
care of other dashboards for medication safety and
help CCGs and practices to achieve improvements in
medication safety [46].
Conclusions
The utilisation of a mixed-methods approach triangu-
lating qualitative and quantitative data allowed for an
in-depth understanding of how the SMASH dash-
board was used and integrated into general practice.
Our study has highlighted how interactions with the
dashboard contributed to making SMASH a sustain-
able intervention with users, focusing on the most
prevalent safety hazards and highest risk (patients
highlighted by more than one indicator) first before
shifting towards resolving new cases and reducing as-
sociated workload In some practices GP staff started
to use the dashboard as resource-intensive pharmacist
activity reduced. These are important findings since
they indicate that the sustainability of such medica-
tion safety dashboards may be achieved by processes
involving flexible integration into practice where
workloads diminish over time, the skills of pharma-
cists are utilised in early stages and collaborative deci-
sion making occurs as the intervention becomes
integrated and embedded.
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